ORGN vs VVOS vs ALGN vs GEVO vs XRAY

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Align Technology, Inc. (ALGN) offers the better valuation at 29. 8x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, DENTSPLY SIRONA Inc.

is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Gevo, Inc.

(GEVO) delivered a total return of -65. 2%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: ALGN returned +123. 3% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 72β versus Origin Materials, Inc. 's 1. 72β — meaning ORGN is approximately 139% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to -441. 2% for Origin Materials, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Align Technology, Inc.

(ALGN) is the more profitable company, earning 10. 2% net margin versus -267. 6% for Origin Materials, Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALGN leads at 15. 3% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, DENTSPLY SIRONA Inc.

(XRAY) trades at 7. 7x forward P/E versus 14. 8x for Align Technology, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORGN: 6238. 0% to $90. 00.

In this comparison, XRAY (5.

9% yield) pays a dividend. ORGN, VVOS, ALGN, GEVO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VVOS: -99. 7%, ORGN: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ORGN (Basic Materials) and VVOS (Healthcare) and ALGN (Healthcare) and GEVO (Basic Materials) and XRAY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ORGN is a small-cap quality compounder stock; VVOS is a small-cap quality compounder stock; ALGN is a mid-cap quality compounder stock; GEVO is a small-cap high-growth stock; XRAY is a small-cap income-oriented stock. XRAY pays a dividend while ORGN, VVOS, ALGN, GEVO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.